Compare Iron Mountain Inc (IRM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs BIO-TECHNE Corp — how do they compare? Iron Mountain Inc trades at $113.5 (market cap $34.46B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Iron Mountain Inc is far larger — about 3× BIO-TECHNE Corp's market cap, and Iron Mountain Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and BIO-TECHNE Corp for 63 Days on average.
| IRM | TECH | |
|---|---|---|
Market Cap | $34.46B | $11.37B |
Volume | 1,379,608 | 3,153,511 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $72.61 |
52-Week Low | $78.86 | $43.31 |
Typical Hold Time | 80 Days | 63 Days |
Enterprise Value | $53.87B | $11.40B |
Dividend Yield | 2.99% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $112.97, down 3.03% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent developments highlight expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus remains bullish with a $142.75 price target, representing 26% upside potential from current levels.
IRM presents a compelling growth story in data center expansion and digital transformation, but faces significant debt burden with 79% debt-to-asset ratio. While institutional ownership is growing and earnings consistently exceed expectations, high valuation multiples and declining profit margins warrant caution. The stock's near-term performance will depend on successful execution of digital initiatives and debt management.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
